Pharmaresearch Bio Co (XKRX:217950) Cash Flow from Financing : ₩-1,364 Mil (TTM As of Dec. 2023)

Pharmaresearch Bio Co Cash Flow from Financing Chart

Pharmaresearch Bio Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Pharmaresearch Bio Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Pharmaresearch Bio Co's Cash from Financing for the quarter that ended in Dec. 2023 is:

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-1,364 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaresearch Bio Co  (XKRX:217950) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Pharmaresearch Bio Co's issuance of stock for the six months ended in Dec. 2023 was ₩359 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Pharmaresearch Bio Co's repurchase of stock for the six months ended in Dec. 2023 was ₩0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Pharmaresearch Bio Co's net issuance of debt for the six months ended in Dec. 2023 was ₩-1,501 Mil. Pharmaresearch Bio Co spent ₩1,501 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Pharmaresearch Bio Co's net issuance of preferred for the six months ended in Dec. 2023 was ₩0 Mil. Pharmaresearch Bio Co paid ₩0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Pharmaresearch Bio Co's cash flow for dividends for the six months ended in Dec. 2023 was ₩0 Mil. Pharmaresearch Bio Co received ₩0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Pharmaresearch Bio Co's other financing for the six months ended in Dec. 2023 was ₩0 Mil. Pharmaresearch Bio Co received ₩0 Mil on other financial activities.

Pharmaresearch Bio Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaresearch Bio Co (XKRX:217950) Business Description